8 results on '"Kyle R. Jackson"'
Search Results
2. Outcomes After Declining a Steatotic Donor Liver for Liver Transplant Candidates in the United States
- Author
-
Mary G. Bowring, Jane J. Long, Jacqueline Garonzik-Wang, Dorry L. Segev, Luckmini Liyanage, Allan B. Massie, Christine E. Haugen, Kyle R. Jackson, Courtenay M. Holscher, Andrew M. Cameron, Benjamin Philosophe, and Shane Ottmann
- Subjects
Male ,medicine.medical_specialty ,Waiting Lists ,Biopsy ,Decision Making ,030230 surgery ,Risk Assessment ,Severity of Illness Index ,Article ,Donor Selection ,End Stage Liver Disease ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,Registries ,Perioperative Period ,Aged ,Transplantation ,medicine.diagnostic_test ,Proportional hazards model ,business.industry ,Hazard ratio ,Perioperative ,Middle Aged ,Allografts ,medicine.disease ,Survival Analysis ,Transplant Recipients ,United States ,Liver Transplantation ,Fatty Liver ,Natural history ,Treatment Outcome ,Liver ,Female ,030211 gastroenterology & hepatology ,Living donor liver transplantation ,business ,Lower mortality ,Follow-Up Studies - Abstract
BACKGROUND. Steatotic donor livers (SDLs, ≥30% macrosteatosis on biopsy) are often declined, as they are associated with a higher risk of graft loss, even though candidates may wait an indefinite time for a subsequent organ offer. We sought to quantify outcomes for transplant candidates who declined or accepted an SDL offer. METHODS. We used Scientific Registry of Transplant Recipients offer data from 2009 to 2015 to compare outcomes of 759 candidates who accepted an SDL to 13 362 matched controls who declined and followed candidates from the date of decision (decline or accept) until death or end of study period. We used a competing risk framework to understand the natural history of candidates who declined and Cox regression to compare postdecision survival after declining versus accepting (ie, what could have happened if candidates who declined had instead accepted). RESULTS. Among those who declined an SDL, only 53.1% of candidates were subsequently transplanted, 23.8% died, and 19.4% were removed from the waitlist. Candidates who accepted had a brief perioperative risk period within the first month posttransplant (adjusted hazard ratio [aHR]: (2.49)3.49(4.89’) P < 0.001), but a 62% lower mortality risk (aHR: (0.31)0.38(0.46’) P < 0.001) beyond this. Although the long-term survival benefit of acceptance did not vary by candidate model for end-stage liver disease (MELD), the short-term risk period did. MELD 6–21 candidates who accepted an SDL had a 7.88-fold higher mortality risk (aHR: (4.80)7.88(12.93’) P < 0.001) in the first month posttransplant, whereas MELD 35–40 candidates had a 68% lower mortality risk (aHR: (0.11)0.32(0.90’) P = 0.03). CONCLUSIONS. Appropriately selected SDLs can decrease wait time and provide substantial long-term survival benefit for liver transplant candidates.
- Published
- 2020
3. Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes
- Author
-
Francis L. Weng, Jacqueline Garonzik-Wang, Matthew Cooper, Jane Long, Eliot Heher, Stanley C. Jordan, Jennifer D. Motter, George S. Lipkowitz, Michael A. Rees, John P. Roberts, Jennifer Verbesey, Pooja Singh, Sandip Kapur, Lloyd E. Ratner, Jennifer K. Chen, David A. Gerber, Tomasz Kozlowski, Mark D. Stegall, Madeleine M. Waldram, Bashir R. Sankari, Niraj M. Desai, Dorry L. Segev, A. Osama Gaber, Jose Oberholzer, Babak J. Orandi, Jose M. El-Amm, Jason R. Wellen, Debra L. Sudan, Adel Bozorgzadeh, R. Pelletier, Enrico Benedetti, Robert A. Montgomery, Mary G. Bowring, Kenneth L. Brayman, Kyle R. Jackson, Marc P. Posner, Beatrice P. Concepcion, J. Harold Helderman, Allan B. Massie, Ty B. Dunn, Christopher L. Marsh, Marc L. Melcher, Karina Covarrubias, Arjang Djamali, and Ron Shapiro
- Subjects
Adult ,Graft Rejection ,Male ,medicine.medical_specialty ,Time Factors ,Human leukocyte antigen ,030230 surgery ,Risk Assessment ,Living donor ,Article ,03 medical and health sciences ,0302 clinical medicine ,Highly sensitized ,HLA Antigens ,Isoantibodies ,Risk Factors ,Internal medicine ,Living Donors ,medicine ,Humans ,Registries ,Healthcare Disparities ,Practice Patterns, Physicians' ,Kidney transplantation ,Quality Indicators, Health Care ,Transplantation ,business.industry ,Proportional hazards model ,Graft Survival ,Hazard ratio ,Middle Aged ,medicine.disease ,Kidney Transplantation ,United States ,Treatment Outcome ,Histocompatibility ,Cohort ,Female ,030211 gastroenterology & hepatology ,business ,Immunosuppressive Agents - Abstract
BACKGROUND Desensitization protocols for HLA-incompatible living donor kidney transplantation (ILDKT) vary across centers. The impact of these, as well as other practice variations, on ILDKT outcomes remains unknown. METHODS We sought to quantify center-level variation in mortality and graft loss following ILDKT using a 25-center cohort of 1358 ILDKT recipients with linkage to Scientific Registry of Transplant Recipients for accurate outcome ascertainment. We used multilevel Cox regression with shared frailty to determine the variation in post-ILDKT outcomes attributable to between-center differences and to identify any center-level characteristics associated with improved post-ILDKT outcomes. RESULTS After adjusting for patient-level characteristics, only 6 centers (24%) had lower mortality and 1 (4%) had higher mortality than average. Similarly, only 5 centers (20%) had higher graft loss and 2 had lower graft loss than average. Only 4.7% of the differences in mortality (P < 0.01) and 4.4% of the differences in graft loss (P < 0.01) were attributable to between-center variation. These translated to a median hazard ratio of 1.36 for mortality and 1.34 of graft loss for similar candidates at different centers. Post-ILDKT outcomes were not associated with the following center-level characteristics: ILDKT volume and transplanting a higher proportion of highly sensitized, prior transplant, preemptive, or minority candidates. CONCLUSIONS Unlike most aspects of transplantation in which center-level variation and volume impact outcomes, we did not find substantial evidence for this in ILDKT. Our findings support the continued practice of ILDKT across these diverse centers.
- Published
- 2020
4. Temporal Trends in Utilization and Outcomes of DCD Livers in the United States
- Author
-
Benjamin Philosophe, Russell Wesson, Jessica M. Ruck, Dorry L. Segev, Jacqueline Garonzik-Wang, Allan B. Massie, Andrew M. Cameron, S. Ottmann, Ahmet Gurakar, Jennifer D. Motter, and Kyle R. Jackson
- Subjects
Adult ,Transplantation ,Brain Death ,Tissue and Organ Procurement ,Proportional hazards model ,business.industry ,medicine.medical_treatment ,Graft Survival ,Physiology ,Odds ratio ,Liver transplantation ,Graft loss ,Circulatory death ,Tissue Donors ,United States ,Multilevel logistic regression ,Liver Transplantation ,Death ,Liver ,medicine ,Humans ,business ,Donor pool ,Retrospective Studies - Abstract
Historically, donation after circulatory death (DCD) livers were frequently discarded because of higher mortality and graft loss after liver transplantation (LT). However, the demand for LT continues to outstrip the supply of "acceptable" organs. Additionally, changes in the donor pool, organ allocation, and clinical management of donors and recipients, and improved clinical protocols might have altered post-DCD-LT outcomes.We studied 5975 recovered DCD livers using US Scientific Registry of Transplant Recipients data from 2005 to 2017, with a comparison group of 78 235 adult donation after brain death (DBD) livers recovered during the same time period. We quantified temporal trends in discard using adjusted multilevel logistic regression and temporal trends in post-LT mortality and graft loss for DCD LT recipients using adjusted Cox regression.DCD livers were more likely to be discarded than DBD livers across the entire study period, and the relative likelihood of discard increased over time (adjusted odds ratio [aOR] of discard DCD versus DBD 3.854.455.14 2005-2007, 5.225.876.59 2015-2017) despite improving outcomes after DCD LT. Mortality risk for DCD LTs decreased in each time period (compared with 2005-2007, aHR 2008-2011 0.720.840.97, aHR 2012-2014 0.480.580.70, aHR 2015-2017 0.340.430.55), as did risk of graft loss (compared with 2005-2007, aHR 2008-2011 0.690.810.94, aHR 2012-2014 0.450.550.67, aHR 2015-2017 0.360.450.56).Despite dramatic improvements in outcomes of DCD LT recipients, DCD livers remain substantially more likely to be discarded than DBD livers, and this discrepancy has actually increased over time. DCD livers are underutilized and have the potential to expand the donor pool.
- Published
- 2021
5. 416.2: Early Clinical Complications Following HLA-Incompatible Living Donor Kidney Transplantation
- Author
-
Jennifer Motter, Kyle R Jackson, Allan B Massie, Jacqueline M Garonzik-Wang, and Dorry L Segev
- Subjects
Transplantation - Published
- 2022
6. Association Between Living Kidney Donor Postdonation Hypertension and Recipient Graft Failure
- Author
-
Yifan Yu, Fawaz Al Ammary, Allan B. Massie, Christine E. Haugen, Tanveen Ishaque, Courtenay M. Holscher, Jacqueline M. Garonzik Wang, Kyle R. Jackson, and Dorry L. Segev
- Subjects
Adult ,Graft Rejection ,Male ,medicine.medical_specialty ,Disease ,Kidney ,Nephrectomy ,Risk Assessment ,Article ,Risk Factors ,Internal medicine ,Diabetes mellitus ,Living Donors ,Medicine ,Humans ,Registries ,Antihypertensive Agents ,Transplantation ,business.industry ,Incidence (epidemiology) ,Incidence ,Hazard ratio ,Graft Survival ,Middle Aged ,medicine.disease ,Kidney Transplantation ,Confidence interval ,Transplant Recipients ,medicine.anatomical_structure ,Blood pressure ,Hypertension ,Tissue and Organ Harvesting ,Kidney Failure, Chronic ,Female ,business ,Risk assessment ,Follow-Up Studies - Abstract
BACKGROUND Recipients of kidneys from living donors who subsequently develop end-stage renal disease (ESRD) also have higher graft failure, suggesting the 2 donor kidneys share risk factors that could inform recipient outcomes. Given that donor ESRD is rare, an earlier and more common postdonation outcome could serve as a surrogate to individualize counseling and management for recipients. Hypertension is a frequent event before donor ESRD; thus, early postdonation hypertension might indicate higher risk of graft failure. METHODS We studied Scientific Registry of Transplant Recipients data to quantify the association between early postdonation hypertension and recipient graft failure using propensity score-weighted Cox proportional hazards regression. We also examined the association between postdonation systolic blood pressure and graft failure. RESULTS Of 37 901 recipients, 2.4% had a donor who developed hypertension within 2 years postdonation. Controlling for donor and recipient characteristics, recipients whose donors developed hypertension had no higher risk for graft failure (adjusted hazard ratio [aHR] 1.03, 95% confidence interval [CI] 0.85-1.25, P = 0.72). This was consistent among subgroups of recipients at higher risk for adverse outcomes due to hyperfiltration: African American recipients (aHR 1.10, 95% CI 0.70-1.73, P = 0.68) and those with ESRD caused by hypertension (aHR 1.10, 95% CI 0.65-1.85, P = 0.73) or diabetes (aHR 0.80, 95% CI 0.56-1.13, P = 0.20). However, graft failure was associated with postdonation systolic blood pressure (per 10 mm Hg, aHR 1.05, 95% CI 1.03-1.08, P < 0.001). CONCLUSIONS Although postdonation systolic blood pressure is associated with graft failure, the reported diagnosis of hypertension as determined by the requirement for blood pressure treatment early postdonation did not portend a higher risk of recipient graft failure in the same way as eventual postdonation ESRD.
- Published
- 2020
7. Posttransplant Outcomes for cPRA-100% Recipients Under the New Kidney Allocation System
- Author
-
Courtenay M. Holscher, Jacqueline Garonzik-Wang, Nada Alachkar, Niraj M. Desai, Dorry L. Segev, Jennifer D. Motter, Allan B. Massie, and Kyle R. Jackson
- Subjects
Prioritization ,Adult ,Graft Rejection ,Male ,medicine.medical_specialty ,Tissue and Organ Procurement ,Waiting Lists ,Delayed Graft Function ,030230 surgery ,Logistic regression ,Resource Allocation ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Highly sensitized ,HLA Antigens ,Risk Factors ,Internal medicine ,Medicine ,Humans ,Registries ,Young adult ,Mortality ,Transplantation ,Proportional hazards model ,business.industry ,Incidence (epidemiology) ,Histocompatibility Testing ,Incidence ,Cold Ischemia ,Graft Survival ,Health Plan Implementation ,Odds ratio ,Middle Aged ,Allografts ,Kidney Transplantation ,United States ,Kidney allocation ,Treatment Outcome ,Kidney Failure, Chronic ,030211 gastroenterology & hepatology ,Female ,business ,Program Evaluation - Abstract
There is concern in the transplant community that outcomes for the most highly sensitized recipients might be poor under Kidney Allocation System (KAS) high prioritization.To study this, we compared posttransplant outcomes of 525 pre-KAS (December 4, 2009, to December 3, 2014) calculated panel-reactive antibodies (cPRA)-100% recipients to 3026 post-KAS (December 4, 2014, to December 3, 2017) cPRA-100% recipients using SRTR data. We compared mortality and death-censored graft survival using Cox regression, acute rejection, and delayed graft function (DGF) using logistic regression, and length of stay (LOS) using negative binomial regression.Compared with pre-KAS recipients, post-KAS recipients were allocated kidneys with lower Kidney Donor Profile Index (median 30% versus 35%, P0.001) but longer cold ischemic time (CIT) (median 21.0 h versus 18.6 h, P0.001). Compared with pre-KAS cPRA-100% recipients, those post-KAS had higher 3-year patient survival (93.6% versus 91.4%, P = 0.04) and 3-year death-censored graft survival (93.7% versus 90.6%, P = 0.005). The incidence of DGF (29.3% versus 29.2%, P = 0.9), acute rejection (11.2% versus 11.7%, P = 0.8), and median LOS (5 d versus 5d, P = 0.2) were similar between pre-KAS and post-KAS recipients. After accounting for secular trends and adjusting for recipient characteristics, post-KAS recipients had no difference in mortality (adjusted hazard ratio [aHR]: 0.861.623.06, P = 0.1), death-censored graft failure (aHR: 0.521.001.91, P0.9), DGF (adjusted odds ratio [aOR]: 0.580.861.27, P = 0.4), acute rejection (aOR: 0.610.941.43, P = 0.8), and LOS (adjusted LOS ratio: 0.981.161.36, P = 0.08).We did not find any statistically significant worsening of outcomes for cPRA-100% recipients under KAS, although longer-term monitoring of posttransplant mortality is warranted.
- Published
- 2019
8. Outcomes After Declining Increased Infectious Risk Kidney Offers for Pediatric Candidates in the United States
- Author
-
Heather L. Wasik, Christine M. Durand, Niraj M. Desai, Kyle R. Jackson, Allan B. Massie, Jacqueline Garonzik-Wang, Alicia M. Neu, Dorry L. Segev, and Mary G. Bowring
- Subjects
Male ,medicine.medical_specialty ,Tissue and Organ Procurement ,Adolescent ,Waiting Lists ,medicine.medical_treatment ,Context (language use) ,Infections ,Risk Assessment ,Article ,Donor Selection ,Interquartile range ,Risk Factors ,Internal medicine ,parasitic diseases ,medicine ,Humans ,Registries ,Child ,Dialysis ,Retrospective Studies ,Transplantation ,Kidney ,Proportional hazards model ,business.industry ,Hazard ratio ,Kidney Transplantation ,Tissue Donors ,Transplant Recipients ,United States ,Survival Rate ,medicine.anatomical_structure ,Infectious risk ,Female ,business - Abstract
BACKGROUND Kidneys from infectious risk donors (IRD) confer substantial survival benefit in adults, yet the benefit of IRD kidneys to pediatric candidates remains unclear in the context of high waitlist prioritization. METHODS Using 2010-2016 Scientific Registry of Transplant Recipients data, we studied 2417 pediatric candidates (age
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.